1 |
Peto J. Cancer epidemiology in the last century and the next decade. Nature2001, 411(6835): 390-395.
|
2 |
Stefaniuk P,Cianciara J,Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol, 2010, 16(4): 418-424.
|
3 |
Rosenberg SA,Yang JC,Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA, 1994, 271(12): 907-913.
|
4 |
Li B,Simmons A,Du T, et al. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Clin Immunol, 2009, 133(2): 184-197.
|
5 |
Liu SQ,Shiraiwa H,Kawai K, et al. Tumor-specific autologous cytotoxic T lymphocytes from tissue section. Nature Med, 1996, 2(12): 1283.
|
6 |
Peng BG,Liu SQ,Kuang M, et al. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res, 2002, 93(4): 363-368.
|
7 |
Kuang M,Peng BG,Lu MD, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res, 2004, 10(5): 1574-1579.
|
8 |
Peng B,Liang L,Chen Z, et al. Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma. Hepatogastroenterology, 2006, 53(69): 409-414.
|
9 |
Slack A,Cervoni N,Pinard M, et al. Feedback regulation of DNA methyltransferase gene expression bymethylation. EurJ Biochem, 1999, 264(1): 191-199.
|
10 |
Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol, 2010, 125(2 Suppl 2): S272-283.
|
11 |
Peng BG,He Q,Liang LI, et al. Induction of cytotoxic T-lymphocyte responses using dendritic cells transfected with hepatocellular carcinoma mRNA. Br J Biomed Sci, 2006, 63(3): 123-128.
|